Norfolk, VA, June 02, 2020 — ReAlta Life Sciences is pleased to have received a Commonwealth Research Commercialization Fund (CRCF) grant. This award will help support the clinical development of ReAlta’s lead compound (PIC1 / RLS-0071) to treat babies suffering hypoxic ischemic encephalopathy, a severe form of birth asphyxia.
Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...Read More
Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...Read More
Norfolk, VA, November 19, 2020 — Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, is...Read More